Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2010128303) MULTI- VALENT ADJUVANT DISPLAY
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

1. An adjuvant-polymer construct comprising a polymer backbone which is covalently linked to 3 or more adjuvants, wherein the 3 or more adjuvants are the same or different and are each present in a pendant side chain, the adjuvants being connected to the polymer backbone either directly or via a spacer group.

2. An adjuvant-polymer construct according to claim 1, wherein the polymer backbone has substantially no adjuvant activity.

3. An adjuvant-polymer construct according to claim 1 or claim 2, wherein the polymer backbone is at least partially water-soluble.

4. An adjuvant-polymer construct according to any one of the preceding claims, wherein the polymer backbone is based on monomer units chosen from (meth)acrylates, (meth)acrylamides, styryl monomers, vinyl monomers, vinyl ether monomers, vinyl ester monomers, sialic acid monomers, mannose monomers, N-(2-hydroxyethyl)-l-glutamine (HEG) monomers, and ethyleneglycol-oligopeptide monomers.

5. An adjuvant-polymer construct according to claim 4, wherein the polymer backbone is based on monomer units chosen from N-2-hydroxypropylmethacrylamide (HPMA), N-(2-hydroxyethyl)-l-glutamine (HEG), and ethyleneglycol, or is a polysialic acid or polymannan polymer.

6. An adjuvant-polymer construct according to any one of the preceding claims, wherein the adjuvants are the same or different and are selected from lipoglycans, lipopolysaccharide, lipoteichoic acid, peptidoglycan, synthetic lipoproteins, zymosan, glycolipids, Polyinosine-polycytidylic acid, monophosphoryl Lipid A, Flagellin, imidazoquinoline-compounds, guanosine, TNF-alpha (or peptides of), IL-2, IL-4, IL-8, CD40, OX40, GM-CSF and CpG-containing sequences in bacterial DNA or synthetic oligonucleotides.

7. An adjuvant-polymer construct according to any one of the preceding claims, wherein the polymer backbone and/or the spacer group(s) contain degradable linkages.

8. An adjuvant-polymer construct according to any one of the preceding claims, wherein the weight average molecular weight of the polymer is from 5 to 4OkDa.

9. An adjuvant-polymer construct according to any one of the preceding claims, wherein the polymer backbone is covalently linked to from 10 to 50 adjuvants, either directly or via a spacer group.

10. An adjuvant-polymer construct according to any one of the preceding claims, wherein the polymer is a branched polymer, for example a dendrimer or comb polymer.

11. An adjuvant-polymer construct according to any one of the preceding claims, wherein the polymer is cross-linked such that it forms a hydrogel.

12. An adjuvant-polymer construct according to any one of the preceding claims, wherein the construct is bound to a vaccine to provide a vaccine conjugate.

13. A composition comprising an adjuvant-polymer construct according to any one of the preceding claims and a pharmaceutically acceptable carrier or diluent.

14. A composition according to claim 13, comprising an adjuvant-polymer construct according to any one of claims 1 to 11, a pharmaceutically acceptable carrier or diluent, and which further comprises a vaccine.

15. A method for stimulating or enhancing an immune response in a subject in need thereof, comprising administering to said subject an effective, non-toxic amount of an adjuvant-polymer construct as defined in any one of claims 1 to 12, or a composition as defined in claim 13 or 14, wherein when the adjuvant-polymer construct or composition does not comprise a vaccine, the method further comprises the step of administering to said patient an effective and non-toxic amount of a vaccine.

16. An adjuvant-polymer construct according to any one of claims 1 to 12 or a composition according to claim 13 or 14, for use in a method of stimulating or enhancing an immune response.

17. An adjuvant-polymer construct or a composition according to claim 16, wherein the adjuvant-polymer construct or composition does not comprise a vaccine, and the method of stimulating or enhancing an immune response additionally comprises administering a vaccine.